Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials

PURPOSE: Ramucirumab is an effective treatment for patients with advanced hepatocellular carcinoma (aHCC) and baseline alpha-fetoprotein (AFP) ≥400 ng/mL. We aimed to identify prognostic and predictive factors of response to ramucirumab in patients with aHCC with AFP ≥400 ng/mL from the phase III RE...

Descripción completa

Detalles Bibliográficos
Autores principales: Llovet, Josep M., Singal, Amit G., Villanueva, Augusto, Finn, Richard S., Kudo, Masatoshi, Galle, Peter R., Ikeda, Masafumi, Callies, Sophie, McGrath, Louise M., Wang, Chunxiao, Abada, Paolo, Widau, Ryan C., Gonzalez-Gugel, Elena, Zhu, Andrew X.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662930/
https://www.ncbi.nlm.nih.gov/pubmed/35247922
http://dx.doi.org/10.1158/1078-0432.CCR-21-4000

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662930/
https://www.ncbi.nlm.nih.gov/pubmed/35247922
http://dx.doi.org/10.1158/1078-0432.CCR-21-4000

Ejemplares similares